Without Your DEA Registration, There Is No Manufacturing Operation.
Dhairya Jani is a former DEA Diversion Enforcement Counsel representing bulk and dosage form manufacturers and importers in DEA administrative enforcement proceedings, civil penalty matters, and quota disputes.
DEA Enforcement at the manufacturer level is not contained to a single facility or product line. When the DEA targets a manufacturer, the consequences extend through the entire supply chain and can affect patient access to critical medications. Jani Law PLLC represents manufacturers from first investigative contact through administrative hearing and final agency order. For quota matters, Jani Law PLLC represents manufacturers in both informal quota redeterminations and formal administrative proceedings before the DEA.
The Regulatory Framework Manufacturers Operate Under
Pharmaceutical manufacturers of controlled substances operate under the most demanding tier of DEA regulatory requirements. Beyond standard registrant obligations, manufacturers face production quota constraints that directly limit what they can produce, when, and in what quantities.
Manufacturer registration is governed by 21 U.S.C. § 823(a) and (e), applying a public interest standard that weighs compliance with applicable state laws, compliance history, manufacturing experience, and maintenance of effective controls against diversion. Enforcement actions at this level often involve large evidentiary records and significant civil penalty exposure under the Controlled Substances Act.
What the DEA Examines in a Manufacturer Enforcement Action
Recordkeeping and Security
Manufacturers must maintain complete, accurate records for all controlled substance production, import, export, and distribution transactions under 21 U.S.C. § 827 and 21 C.F.R. §§ 1304.03–1304.33.
Physical security requirements for Schedules I and II controlled substances under 21 C.F.R. § 1301.72 are among the most stringent in the entire DEA regulatory framework.
The gap between written security policy and actual operational execution is where enforcement cases are built.
Loss and Theft Reporting
Significant controlled substance losses must be reported to DEA promptly. What constitutes a significant loss in a manufacturing context, as distinct from minor inventory discrepancies and normal process variation, is not defined by a single objective regulatory standard and has been the subject of DEA enforcement proceedings. Under-reporting creates enforcement exposure. Over-reporting creates an unnecessary compliance record. Counsel who understands this regulatory landscape can help navigate that determination before a report goes out.
Diversion Controls
Manufacturers must maintain effective controls against diversion throughout the production and distribution process, from raw material receipt through finished product shipment. The adequacy of those controls is evaluated on both the written policy and actual operational execution. The gap between the two is where enforcement cases are built.
How Jani Law PLLC Represents Pharmaceutical Manufacturers
- Order to Show Cause (OSC) defense and Immediate Suspension Order (ISO) response through full administrative law judge hearing, Recommended Decision, and Administrator’s Final Order
- Investigation and inspection response, including scope management, document control, privilege analysis, and strategic management of the investigative record from the first DEA contact
- Administrative subpoena response, including scope and legal authority analysis to ensure the response is legally sound
- Corrective Action Plan development designed to support negotiated resolution where the facts permit
- Memorandum of Agreement (MOA) negotiation, including term-by-term review, operational impact analysis, and compliance program design that meets MOA obligations without creating additional exposure
- Civil penalty matters: advising on civil penalty exposure under 21 U.S.C. § 842(c) and ensuring the administrative defense accounts for civil consequences from day one
Manufacturing and Procurement Quota Representation
Under 21 U.S.C. § 826, the DEA establishes Aggregate Production Quotas (APQs) for each Schedule I and II controlled substance annually and allocates Individual Manufacturing Quotas (IMQs) to specific registrants. Manufacturers requiring raw material or active pharmaceutical ingredient (API) inputs must separately apply for procurement quotas, which govern the quantity of Schedule I and II controlled substances a manufacturer registrant may purchase or otherwise acquire for manufacturing purposes. This layered structure directly constrains manufacturing capacity, supply chain planning, research timelines, and the ability to respond to demand shifts.
Manufacturers routinely find that DEA quota allocations do not keep pace with actual medical demand. When patient populations grow, prescribing patterns shift, or new clinical applications emerge, allocations can fall behind. Quota proceedings require the same level of preparation and documentation as any other DEA regulatory matter, and engaging counsel early in the process is where the strongest applications are built.
Quota Representation
Having experienced counsel develop records before submitting annual quota applications or seeking engagement with the DEA on redeterminations is where the groundwork for a strong outcome is laid.
- Annual IMQ applications, including application preparation and evidentiary record development
- Procurement quota applications, including raw material and API precursor documentation and demand projections coordinated with upstream suppliers
- Counsel for informal quota redeterminations and engagement with DEA Diversion Control
Protect Your Reputation as a Pharmaceutical Manufacturer: Contact Jani Law PLLC
If you are a pharmaceutical manufacturer facing DEA enforcement or a quota dispute, Jani Law PLLC is on your side. As a former DEA Diversion Enforcement Counsel, Dhairya Jani brings firsthand experience of how these cases are built and where they can be challenged to defend your business and professional reputation. To request a free, confidential consultation, contact our law firm today.